10 Best Biotech Stocks Under $10

Published September 27, 2021 at 2:01 pm EDT Updated September 7, 2026 at 12:58 pm EDT

In this article, we discuss the 10 best biotech stocks under $10.

Biotech stocks are facing a decline in September after Biogen gave a disappointing outlook for near-term sales of its Alzheimer’s disease treatment Aduhelm. The sector also took a hit after the Biden administration announced plans to further regulate drug prices. However, this could present an attractive entry point into biotech stocks for long-term investors.

Healthcare stocks have always been on the investors’ radar due to the long-term potential growth they offer. Especially, due to the onset of Covid-19 in 2020, the stock market witnessed a renewed interest in the healthcare sector, with biotech stocks maintaining their preeminence. The biotech industry encompasses the companies that develop drugs and therapies for treatments of different medical conditions. Some of the notable biotech companies include AstraZeneca PLC (NASDAQ: AZN), AbbVie Inc. (NYSE: ABBV), Abbott Laboratories (NYSE: ABT) and Merck & Co. (NYSE: MRK).

Moreover, the biotech sector has generated profitable returns for the shareholders in the past. NASDAQ Biotechnology Index (NBI), which represents 98% of all U.S. listed biotech companies, was up 73% of the time in the past 27 years, according to a report by Torreya Partners LLC.

Some of the notable biotech stocks under $10 include Amarin Corporation plc (NASDAQ: AMRN), Mersana Therapeutics, Inc. (NASDAQ: MRSN), Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Savara Inc. (NASDAQ: SVRA).

Our Methodology:

Let’s analyze our list of the 10 best biotech stocks under $10. We took into account hedge fund sentiments, analysts’ ratings, long-term growth potential, and fundamentals while choosing these stocks.

Photo by National Cancer Institute on Unsplash

Why pay attention to hedge fund sentiment while choosing stocks?

Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 86 percentage points since March 2017. Between March 2017 and July 2021, our monthly newsletter’s stock picks returned 186.1%, vs. 100.1% for the S&P 500 ETF (SPY). Our stock picks outperformed the market by more than 86 percentage points (see the details here). That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.

10 Best Biotech Stocks Under $10

10. Anixa Biosciences, Inc. (NASDAQ: ANIX)

Number of Hedge Fund Holders: 2

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a biotech company that develops therapies and vaccines to treat unmet and serious oncological and infectious diseases. The company utilizes the latest technological developments to further enhance the efficacy of its treatments. Anixa Biosciences, Inc. ranks tenth on our list of the best biotech stocks under $10.

Recently, Anixa Biosciences, Inc. carried out a genomic variant analysis which showed the efficacy of its potential Covid-19 compounds against the Delta variant. In August, HC Wainwright lifted its price target on Anixa Biosciences, Inc. to $11, with a ‘Buy’ rating on the shares.

As of Q2 2021, 2 hedge funds tracked by Insider Monkey have positions in Anixa Biosciences, Inc., worth $722,000. The number of hedge funds remained the same in the previous quarter, with a total value of $156,000. Jim Simons’ Renaissance Technologies is the company’s largest shareholder, with shares worth $483,000.

Like AstraZeneca PLC, Amarin Corporation plc (NASDAQ: AMRN), AbbVie Inc., BioDelivery Sciences International, Inc., Abbott Laboratories, Merck & Co., and Johnson & Johnson, Anixa Biosciences, Inc. is one of the notable biotech stocks gaining investors’ attention in 2021.

9. Brickell Biotech, Inc. (NASDAQ: BBI)

Number of Hedge Fund Holders: 4

Brickell Biotech, Inc. (NASDAQ: BBI) is an American biotech company that is focused on developing prescription therapeutics for dermatological diseases. Along with this, the company also develops novel therapies for autoimmune and other debilitating diseases. Brickell Biotech, Inc. ranks ninth on our list of the best biotech stocks under $10.

Recently, Brickell Biotech, Inc. inked an agreement with Voronoi, Inc., a Korean biotech company, to manufacture new kinase inhibitors. This agreement would grant the company to expand its research and developments to global markets. In Q2 2021, Brickell Biotech, Inc. reported revenue of $0.15 million, beating the market estimates by $0.1 million. Recently, Lake Street rated the stock as a ‘Buy’, with a $6 price target due to the company’s significant agreement with Voronoi Inc.

The number of hedge funds having stakes in Brickell Biotech, Inc. increased to 4 in Q2 2021, compared with 2 in the previous quarter. The total value of these stakes is $1.6 million.

8. Savara Inc. (NASDAQ: SVRA)

Number of Hedge Fund Holders: 12

Savara Inc. stands eighth on our list of the best biotech stocks under $10. It is a clinical-stage biotech company focused on developing treatments for rare respiratory diseases. The company has significant experience in orphan drug development and pulmonary medicine.

Recently, Piper Sandler lifted its price target on Savara Inc. to $7, with an ‘Overweight’ rating on the shares. Yasmeen Rahimi, the firm’s analyst, turned ‘even more bullish’ on the stock due to the company’s Phase 3 study of IMPALA-2, a drug to evaluate the efficacy and safety of molgramostim. In Q2 2021, Savara Inc. posted a GAAP EPS of -$0.07, beating the estimates by $0.05.

As of Q2 2021, 12 hedge funds tracked by Insider Monkey have positions in Savara Inc., up from 10 in the previous quarter. The total value of these stakes is $28.9 million.

7. CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

Number of Hedge Fund Holders: 13

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is an American biopharmaceutical company that develops and markets therapeutics addressing serious medical conditions, such as cancer. The company sells oncology drugs and drug candidates in Hong Kong, Taiwan, China, and Macau. CASI Pharmaceuticals, Inc. ranks seventh on our list of the best biotech stocks under $10.

In Q2 2021, CASI Pharmaceuticals, Inc. posted a GAAP EPS of -$0.05, beating the estimates by $0.02. The consolidated revenue of $7.16 million presented a 168.2% year-over-year growth. In May, BTIG initiated its coverage of CASI Pharmaceuticals, Inc. with a ‘Buy’ rating and a $4 price target. The firm’s analyst, Justin Zelin noted that the company’s major revenue comes from Evomela, a chemotherapy drug used to treat multiple myeloma. In the second quarter, Evomela sales resulted in a 173% growth in gross revenue, compared with 2020 levels.

Of the 873 hedge funds tracked by Insider Monkey, 13 hedge funds have positions in CASI Pharmaceuticals, Inc. as of Q2 2021, up from 10 in the previous quarter. The stakes are valued at $23.8 million. Mitchell Blutt’s Consonance Capital Management is the company’s largest shareholder, with 10.3 million shares, worth $15.9 million.

In addition to AstraZeneca PLC, Amarin Corporation plc (NASDAQ: AMRN), AbbVie Inc., BioDelivery Sciences International, Inc., Abbott Laboratories, Merck & Co., and Johnson & Johnson, analysts and investors are also paying attention to CASI Pharmaceuticals, Inc. amid the company’s long-term growth potential.

6. Viking Therapeutics, Inc. (NASDAQ: VKTX)

Number of Hedge Fund Holders: 13

Viking Therapeutics, Inc. (NASDAQ: VKTX) is an American biotechnology company that is focused on the development of novel and orally available therapies for the treatment of metabolic and endocrine disorders. The company ranks sixth on our list of the best biotech stocks under $10.

In July, BTIG listed Viking Therapeutics, Inc. amongst its top picks in the biotech sector, especially the companies working in the field of non-alcoholic steatohepatitis (NASH). The firm resumed its coverage of the stock with a ‘Buy’ rating and a $20 price target this July. In Q2 2021, Viking Therapeutics, Inc. posted a GAAP EPS of -$.20, in-line with the estimates. The company ended the quarter with cash equivalents and short-term investments of $228.3 million.

As of Q2 2021, 13 hedge funds tracked by Insider Monkey have positions in Viking Therapeutics, Inc., worth roughly $30 million. The number of hedge fund holders remained the same in the previous quarter, with a total value of $33.2 million. Park West Asset Management is the company’s leading shareholder, with 1.6 million shares, worth $9.9 million.

5. Mersana Therapeutics, Inc. (NASDAQ: MRSN)

Number of Hedge Fund Holders: 28

Mersana Therapeutics, Inc. ranks fifth on our list of the best biotech stocks under $10. It is a biotechnology company that specializes in the discovery and development of antibody-drug conjugate (ADC) therapies for cancer patients. The company has headquarters in Massachusetts, U.S.

In August, H.C. Wainwright initiated its coverage on Mersana Therapeutics, Inc. with a ‘Buy’ rating and a $28 price target, and sees 115% upside. The firm likes the company’s Dolaflexin platform that is meant to enhance the efficacy and safety of ADCs. In Q2 2021, Mersana Therapeutics, Inc. reported Research and Development expenses of $32 million, up from $15.4 million during the same period last year. At the end of the quarter, the company had $227.4 million in cash and equivalents.

As of Q2 2021, 28 hedge funds tracked by Insider Monkey have positions in Mersana Therapeutics, Inc., up from 25 in the previous quarter. The total value of these stakes is $294.7 million. VenBio Select Advisor is the company’s largest shareholder, with 6.8 million shares, worth $92.3 million.

4. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

Number of Hedge Fund Holders: 15

Infinity Pharmaceuticals, Inc. is an innovative and clinical-stage biopharmaceutical company that develops and delivers medicines for the treatment of rare and serious diseases. The company uses scientific expertise to develop novel small molecule drugs that target emerging disease pathways. Infinity Pharmaceuticals, Inc. stands fourth on our list of the best biotech stocks under $10.

In August, JPMorgan upgraded Infinity Pharmaceuticals, Inc. to ‘Overweight’ with a $6 price target. The firm’s analyst, Anupam Rama noted the prospects of the company’s oral drug, which is currently undergoing mid-stage studies in urothelial cancer. In Q2 2021, Infinity Pharmaceuticals, Inc. posted a GAAP EPS of -$0.13, beating the estimate by $0.01. The company reported revenue of $0.51 million, presenting a 41.7% year-over-year growth. For FY21, Infinity Pharmaceuticals, Inc. expects a net loss in the range of $40 million to $50 million. Since the beginning of the year, Infinity Pharmaceuticals, Inc. delivered a 74.8% return to shareholders, while its 12-month returns stood at 231.7%.

As of Q2 2021, 15 hedge funds tracked by Insider Monkey have positions in Infinity Pharmaceuticals, Inc., worth $60.1 million. The number of hedge funds remained the same in the previous quarter. Oaktree Capital Management is the company’s largest shareholder, with over 25 million shares, worth $256.7 million.

3. BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

Number of Hedge Fund Holders: 14

BioDelivery Sciences International, Inc. ranks third on our list of the best biotech stocks under $10. It is a rapidly growing specialty biotechnology company that manufactures and markets pharmaceuticals, vaccines, and drug products. The company plans to explore therapies for serious chronic conditions in the future.

In August, BioDelivery Sciences International, Inc. was granted $24 million from the U.S. Department of Veteran Affairs for the pharmaceutical preparation, which would extend till 2026. In Q2 2021, BioDelivery Sciences International, Inc. posted an EPS of $0.12, beating the estimates by $0.05. The company generated revenue of $41.4 million, presenting a 13.3% year-over-year growth. Recently, HC Wainwright boosted its price target on BioDelivery Sciences International, Inc., to $6.00 from $5.50, while keeping a ‘Buy’ rating on the shares. BioDelivery Sciences International, Inc. soared 7% in the past six months.

With 9.5 million shares, worth $$34.1 million, Deerfield Management is the company’s leading shareholder. As of Q2 2021, 14 hedge funds tracked by Insider Monkey have positions in BioDelivery Sciences International, Inc., worth $53.1 million. In the previous quarter, 15 hedge funds held stakes in the company, valued at $63.9 million.

2. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE)

Number of Hedge Fund Holders: 16

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. The company was founded in 2013 and has headquarters in Texas, U.S. It ranks second on our list of the best biotech stocks under $10.

Earlier this year, Aeglea BioTherapeutics, Inc. signed an agreement with a Swedish pharmaceutical company, Immedica Pharma AB to commercialize pegzilarginase for the treatment of Arginase 1 deficiency in Europe. The medicine is currently in phase 3 of development. At the end of Q2, Aeglea BioTherapeutics, Inc. had available cash and cash equivalents of $130.4 million. In August, Evercore ISI initiated its coverage on Aeglea BioTherapeutics, Inc. with a ‘Buy’ rating and a $20 price target.

Of the 873 hedge funds tracked by Insider Monkey, 16 hedge funds have positions in Aeglea BioTherapeutics, Inc. as of Q2 2021. The total value of these stakes is $139.9 million. This number of hedge funds is compared with 18 hedge funds having stakes in the company, valued at $153.2 million. Samuel Isaly’s OrbiMed Advisors is the company’s leading shareholder with over 4 million shares, worth $27.9 million.

1. Amarin Corporation plc (NASDAQ: AMRN)

Number of Hedge Fund Holders: 21

Amarin Corporation plc (NASDAQ: AMRN) tops our list of the best biotech stocks under $10. It is a rapidly growing, innovative biotech company that focuses on developing and commercializing cost-effective therapies to improve patients’ health. The company’s lead product, VASCEPA, is made to address cardiovascular risk for patients globally.

Recently, SVB Leerink initiated its coverage on Amarin Corporation plc (NASDAQ: AMRN), with an ‘Outperform’ rating and a $12 price target. The firm’s analyst believes that the company’s VASCEPA will help achieve improved cardiovascular risk outcomes. In Q2 2021, Amarin Corporation plc (NASDAQ: AMRN) posted an EPS of $0.03, beating the consensus by $0.06. The consolidated revenue presented a 14.2% year-over-year growth at $154.4 million. The company plans to launch VASCEPA in Europe (as VAZKEPA) this September, starting from Germany. Currently traded at $5.30, Amarin Corporation plc (NASDAQ: AMRN) gained 29.9% in the last year.

As of Q2 2021, 21 hedge funds tracked by Insider Monkey have positions in Amarin Corporation plc (NASDAQ: AMRN), worth $298.4 million. In the previous quarter, 21 hedge funds held stakes in the company, worth $444.2 million.

You can also take a look at 10 Best Small-Cap Biotech Stocks Under $10 in 2021 and 15 Fastest Growing Biotech Companies in the US

Follow Insider Monkey on Twitter

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the "biggest technological advance in my lifetime," more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year's worth of in-depth investment research and exclusive insights – that's less than a single fast food meal!

Here's why this is a deal you can't afford to pass up:

Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock's groundbreaking technology and massive growth potential.

11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter's portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

Bonus Reports: Premium access to members-only fund manager video interviews

Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

30-Day Money-Back Guarantee: If you're not absolutely satisfied with our service, we'll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait - because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don't let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here's what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you're backed by our ironclad 30-day money-back guarantee.

Don't miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Share

10 Best Biotech Stocks Under $10

10. Anixa Biosciences, Inc. (NASDAQ: ANIX)

9. Brickell Biotech, Inc. (NASDAQ: BBI)

8. Savara Inc. (NASDAQ: SVRA)

7. CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

6. Viking Therapeutics, Inc. (NASDAQ: VKTX)

5. Mersana Therapeutics, Inc. (NASDAQ: MRSN)

4. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

3. BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

2. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE)

1. Amarin Corporation plc (NASDAQ: AMRN)

Share